Paving a pathway for drug development in HER2-positive biliary tract cancer

Lancet Oncol. 2021 Sep;22(9):1204-1206. doi: 10.1016/S1470-2045(21)00465-4.

Authors

Christopher T Chen¹, Lipika Goyal²

Affiliations

¹ Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA.
² Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. Electronic address: lgoyal@partners.org.

PMID: 34478661
DOI: 10.1016/S1470-2045(21)00465-4

No abstract available

Publication types

Comment

MeSH terms

Biliary Tract Neoplasms* / drug therapy
Biliary Tract Neoplasms* / genetics
Drug Development
Humans
Receptor, ErbB-2

Substances

Receptor, ErbB-2